Trial *
Publication Pupim L, Ann. Rheum. Dis (2021) (published paper)

Funding: Not reported/unclear
Conflict of interest: Yes

Methods
RCT
Blinding: double blinding
Location : Multicenter / USA, Brazil, Chile, Peru, and South Africa
Follow-up duration (days): 28
Inclusion criteria
  • Adults
  • hospitalized with severe COVID-19 pneumonia and hyperinflammation
  • requiring supplemental oxygen therapy without mechanical ventilation
Exclusion criteria
  • Patients requiring mechanical ventilation
Interventions
Treatment
Mavrilimumab
6 or 10 mg/kg intravenously once-off
Control
Placebo

Participants
Randomized
NR

Analyzed
114 participants Mavrilimumab=75
Placebo=39
Characteristics of participants
N= 114
Mean age : NR
0 males
Severity : Mild: n=0 / Moderate: n=* / Severe: n=* Critical: n=0
Number of vaccinated participants: NR
Primary outcome
In the register
NR
In the report
Proportion of patients alive and free of mechanical ventilation at Day 29
Documents
available

Protocol

NR

Statistical plan

NR

Data-sharing willing stated in the publication:

Not reported
Risk of bias
Overall
The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review
*
General comment The conference abstract was available for data extraction and risk of bias assessment. The trial is described as ongoing in the abstract. No registry, protocol or statistical analysis plan was available. The trial included patients with severe COVID-19 requiring supplemental oxygen and mechanical ventilation; only those not requiring mechanical ventilation are included in this report. Unclear whether the study achieved its sample size and unclear number of patients randomized and analyzed. No outcomes were extracted.